AstraZeneca’s Forxiga wins approval in China for heart failure treatment

AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular ... Read More